Dossier
AP01
Coverage of AP01 in the Nexus archive.
- Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO
Avalyn, a drugmaker backed by Novo, raised $300 million in an upsized IPO. Its drug AP01 has completed a clinical trial for idiopathic pulmonary fibrosis.